Roth Capital Predicts Higher Earnings for Fortress Biotech

Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Investment analysts at Roth Capital increased their Q2 2025 earnings estimates for shares of Fortress Biotech in a note issued to investors on Tuesday, May 20th. Roth Capital analyst J. Wittes now expects that the biopharmaceutical company will post earnings per share of ($0.31) for the quarter, up from their previous forecast of ($0.43). The consensus estimate for Fortress Biotech's current full-year earnings is ($3.28) per share. Roth Capital also issued estimates for Fortress Biotech's Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($1.20) EPS and FY2026 earnings at ($0.45) EPS.

Separately, Roth Mkm reiterated a "buy" rating and issued a $16.00 price target (up from $15.00) on shares of Fortress Biotech in a report on Tuesday, March 11th.

Fortress Biotech Stock Up 4.2%

NASDAQ FBIO traded up $0.08 on Thursday, reaching $1.86. The company had a trading volume of 123,275 shares, compared to its average volume of 407,437. The stock has a market capitalization of $54.85 million, a PE ratio of -0.61 and a beta of 1.85. The firm's 50 day moving average price is $1.64 and its 200 day moving average price is $1.76. Fortress Biotech has a 12 month low of $1.33 and a 12 month high of $2.89.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.53. The company had revenue of $15.12 million during the quarter, compared to the consensus estimate of $16.30 million.

Hedge Funds Weigh In On Fortress Biotech

A number of institutional investors and hedge funds have recently made changes to their positions in the business. HB Wealth Management LLC grew its stake in shares of Fortress Biotech by 6.1% in the 1st quarter. HB Wealth Management LLC now owns 113,350 shares of the biopharmaceutical company's stock worth $177,000 after buying an additional 6,500 shares in the last quarter. PFG Investments LLC grew its stake in shares of Fortress Biotech by 28.4% in the 1st quarter. PFG Investments LLC now owns 45,259 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 10,000 shares in the last quarter. Wolverine Trading LLC purchased a new position in shares of Fortress Biotech in the 4th quarter worth $26,000. PVG Asset Management Corp grew its stake in shares of Fortress Biotech by 3.3% in the 4th quarter. PVG Asset Management Corp now owns 386,295 shares of the biopharmaceutical company's stock worth $782,000 after buying an additional 12,505 shares in the last quarter. Finally, Integrated Wealth Concepts LLC grew its stake in shares of Fortress Biotech by 28.9% in the 4th quarter. Integrated Wealth Concepts LLC now owns 59,400 shares of the biopharmaceutical company's stock worth $120,000 after buying an additional 13,300 shares in the last quarter. 96.51% of the stock is owned by hedge funds and other institutional investors.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.